7 employees
Specific Biologics develops novel gene editing technologies to treat diseases at the genetic level in cells inside the body.
2017
Specific Biologics raised undisclosed on December 16, 2021
Investors: adMare BioInnovations and Lumira Ventures
Specific Biologics raised undisclosed on June 3, 2020
Investors: Creative Destruction Lab